Biologics in current therapy for inflammatory bowel disease

Tadakazu Hisamatsu, Toshifumi Hibi

Research output: Contribution to journalReview articlepeer-review


Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.

Original languageEnglish
Pages (from-to)168-179
Number of pages12
JournalJapanese Journal of Clinical Immunology
Issue number3
Publication statusPublished - 2009


  • Biologics
  • Inflammatory bowel disease
  • TNFα

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Biologics in current therapy for inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this